Anixa Biosciences Inc. (ANIX)
The price, the headline numbers and the latest news, in one place.
Anixa Biosciences Inc. (ANIX) Stock Price, Analysis & Data
No data available
| Bid | 2.68 |
| Market Cap | 124.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.03M |
| 0.52 | |
| -0.3 | |
| n/a | |
| -11.82 | |
| P/B (ttm) | 8.58 |
| P/S (ttm) | n/a |
| Earnings Date | Sep 9, 2026 |
| Ask | 4.62 |
| Volume | 182,554 |
| Avg. Volume (20D) | 239,906 |
| Open | 3.71 |
| Previous Close | 3.59 |
| Day's Range | 3.60 - 3.75 |
| 52-Week Range | 2.32 - 5.46 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ANIX
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast canc...
Financial Performance
In 2025, Anixa Biosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -10.93M, a decrease of -12.96%.
Financial StatementsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.07 exceeds estimates by 0.03, with 22.22% YoY growth.
Analysts project revenue of ... Upgrade
1 month ago · Pharmaceutical Technology
Anixa Biosciences secures Korean patent for breast cancer vaccineThe patent expands Anixa’s IP portfolio beyond the US and existing international markets.
